JYNT
The Joint Corp.
JYNT has the edge over OSCR overall, supported by stronger valuation and lower modeled downside.
OSCR
Oscar Health, Inc.
OSCR offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
JYNT Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Healthy |
JYNT's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
JYNT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 21x | $6.69 | — |
| Current | 33x | $6.69 | — |
| Cheap | 44x | $8.80 | +32% |
| Fair | 70x | $13.93 | +108% |
| Expensive | 110x | $22.06 | +230% |
Historical ranges are pointers, not guarantees.
JYNT's PE is in its cheap range at 33x. If earnings grow as analysts expect, today's price would be 21x next year's earnings.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over JYNT in the historical PE scenario, which offers more potential upside but is not a forecast.
JYNT Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect JYNT's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over JYNT on the outlook, with more favorable revenue expectations.
JYNT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.33 | +63% |
| Q3 2026 | $0.20 | +54% |
| Q2 2026 | $0.27 | +$0.41 |
| Q1 2026 | $0.23 | +$0.62 |
| Q4 2025 | $0.20 | +$0.59 |
| Q3 2025 | $0.13 | +$1.26 |
| Q2 2025 | -$0.14 | +$0.83 |
| Q1 2025 | -$0.39 | +$0.36 |
| Q4 2024 | -$0.39 | +$0.26 |
JYNT has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
JYNT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $13.6M | +1.3% |
| Q2 2026 | $15.2M | +14% |
| Q1 2026 | $14.8M | +13% |
| Q4 2025 | $15.2M | +3.1% |
| Q3 2025 | $13.4M | -56% |
| Q2 2025 | $13.3M | -56% |
| Q1 2025 | $13.1M | -56% |
| Q4 2024 | $14.7M | -52% |
JYNT's revenue has grown year over year for four quarters in a row: $14M last quarter, up 1.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 9.8% | +8.6 points |
| Q2 2026 | -2.4% | +6.2 points |
| Q1 2026 | 5.9% | +11 points |
| Q4 2025 | 4.9% | -0.6 points |
| Q3 2025 | 1.2% | +12 points |
| Q2 2025 | -8.6% | +3 points |
| Q1 2025 | -5.2% | -8.9 points |
| Q4 2024 | 5.5% | +6 points |
JYNT has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over JYNT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
JYNT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$508.6K | -135% |
| Q2 2026 | $1.9M | +432% |
| Q1 2026 | -$1.7M | +$2.3M |
| Q4 2025 | $2.5M | -34% |
| Q3 2025 | $1.5M | -55% |
| Q2 2025 | $363.6K | +$1.6M |
| Q1 2025 | -$4M | -267% |
| Q4 2024 | $3.8M | +73% |
JYNT usually generates cash, though not every quarter: the latest was −$508,635, but it generated $2M over the past year.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over JYNT on cash flow, with more consistent year-over-year improvement.
JYNT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.5% | -215K shares |
| 1 year | -8.9% | -1.4M shares |
| 3 years | -6.6% | -984K shares |
| 5 years | -6.3% | -938K shares |
| Available history | -3% | -436K shares |
JYNT has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.8M |
| Q2 2026 | $676,810 |
| Q1 2026 | $1.1M |
| Q4 2025 | $9M |
| Q3 2025 | $2.3M |
| Q2 2025 | — |
| Q1 2025 | $8,440 |
| Q4 2024 | — |
JYNT spent $15M buying back its own shares over the past year, about six times what it spent the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
JYNT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.5x | Net Cash |
| Q2 2026 | -7.1x | Net Cash |
| Q1 2026 | -8.9x | Net Cash |
| Q4 2025 | -31.2x | Net Cash |
| Q3 2025 | -39.9x | Net Cash |
| Q3 2024 | -180.9x | Net Cash |
| Q2 2024 | -5.0x | Net Cash |
| Q1 2024 | -2.5x | Net Cash |
JYNT has the edge over OSCR on leverage, with a lower net debt burden relative to earnings.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
JYNT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.4 | Neutral |
| Stochastic | 9.3 | Oversold |
JYNT's weekly RSI is 32 (neutral) and its Stochastic is 9 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
JYNT PE vs Healthcare Sector
| Metric | JYNT | Sector median | Relative |
|---|---|---|---|
| PE | 33x | 26x | 29% above |
| PE % | 5 | 29 | 24 pts below |
JYNT is trading at 33x earnings, a 29% premium to the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over JYNT on valuation relative to its sector.
JYNT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $7.17 | 6.7% below |
| 20 week MA | $7.96 | 16% below |
| 50 week MA | $8.54 | 22% below |
| 100 week MA | $9.49 | 30% below |
| 200 week MA | $10.9 | 39% below |
JYNT is in a downtrend: it's below all five of its weekly moving averages, and 39% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over JYNT on trend strength, trading above more of its moving averages.
JYNT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $16.3 | $25.5 | +57% |
| 2021 | $25.5 | $64.7 | +153% |
| 2022 | $64.7 | $15.1 | -77% |
| 2023 | $15.1 | $9.61 | -36% |
| 2024 | $9.61 | $9.90 | +3% |
| 2025 | $9.90 | $8.76 | -12% |
| 2026 YTD | $8.76 | $6.69 | -24% |
JYNT's yearly returns have swung widely, from +153% in 2021 to −77% in 2022. It's down 24% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over JYNT on returns for 2026, with the stronger performance.